SAM
PTCT icon

Smartleaf Asset Management’s PTC Therapeutics PTCT Stock Holding History

Smartleaf Asset Management’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$76.5K Hold
938
– – ﹤0.01% 1291
2026
Q1 		$61.6K Buy
938
+17
+2% +$1.2K ﹤0.01% 1344
2025
Q4 		$70.2K Buy
921
+452
+96% +$32.8K ﹤0.01% 1383
2025
Q3 		$28.4K Buy
469
+236
+101% +$12.3K ﹤0.01% 1666
2025
Q2 		$11.6K Sell
233
-391
-63% -$18.6K ﹤0.01% 1777
2025
Q1 		$33.8K Buy
624
+11
+2% +$549 ﹤0.01% 1349
2024
Q4 		$28.1K Buy
613
+270
+79% +$11.6K ﹤0.01% 1467
2024
Q3 		$12.9K Sell
343
-30
-8% -$1K ﹤0.01% 1615
2024
Q2 		$12.9K Buy
373
+355
+1,972% +$11.5K ﹤0.01% 1274
2024
Q1 		$529 Buy
+18
New +$504 ﹤0.01% 1732

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Smartleaf Asset Management's PTCT Position: Q2 2026 in Review

Smartleaf Asset Management held its PTC Therapeutics (PTCT) position steady in Q2 2026 at 938 shares worth $76.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1291.

Smartleaf Asset Management first reported a position in PTCT in Q1 2024 and has held it in 10 quarters since. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • Smartleaf Asset Management held 938 shares of PTC Therapeutics worth $76.5K as of Q2 2026.
  • Smartleaf Asset Management left its PTC Therapeutics share count unchanged in Q2 2026.
  • PTC Therapeutics made up ﹤0.01% of Smartleaf Asset Management's portfolio in Q2 2026, its #1291 holding.
  • Smartleaf Asset Management first reported a position in PTC Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Smartleaf Asset Management's 13F filing for Q2 2026, filed 12 Aug 2026.